Jain P C, Khandelwal Y, Tripathi O N
J Med Chem. 1978 Jan;21(1):68-72. doi: 10.1021/jm00199a012.
Threo- and erythro-2-(alpha-hydroxybenzyl)-3,3-dimethylaziridines (1a and 1b) and threo-2-[alpha-hydroxy(2-naphthyl)methyl]- and 2-[alpha-hydroxy(3,4-dichlorobenzyl)]-3,3-dimethylaziridines (1d and 1c) have been prepared as conformationally restricted analogues of beta-adrenoceptor blocking agents like dichloroisoproterenol (DCI) and pronethalol. The aziridine analogues 1 except possibly 1c are competitive antagonists of isoproterenol-induced response on a guinea pig tracheal chain preparation and the order of potency is 1d greater than 1a greater than or equal to 1b greater than propranolol greater than 1c. Unlike propranolol, these compounds have no effect on the isoproterenol-induced response on guinea pig auricles and no significant local anesthetic and antiarrhythmic activity. The aziridine analogues 1 represent the first of a new class of selective beta2-adrenoceptor blocking agents.
已制备了苏式和赤式-2-(α-羟基苄基)-3,3-二甲基氮丙啶(1a和1b)以及苏式-2-[α-羟基(2-萘基)甲基]-和2-[α-羟基(3,4-二氯苄基)]-3,3-二甲基氮丙啶(1d和1c),作为β-肾上腺素受体阻断剂如二氯异丙肾上腺素(DCI)和心得宁的构象受限类似物。氮丙啶类似物1(可能1c除外)是异丙肾上腺素诱导的豚鼠气管链制剂反应的竞争性拮抗剂,效力顺序为1d大于1a大于或等于1b大于普萘洛尔大于1c。与普萘洛尔不同,这些化合物对异丙肾上腺素诱导的豚鼠耳廓反应无影响,且无明显的局部麻醉和抗心律失常活性。氮丙啶类似物1代表了一类新型选择性β2-肾上腺素受体阻断剂中的首个化合物。